AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06019130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
Study NCT06019130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluoruracil during induction chemotherapy in all groups except of adults > 25 years with metastatic disease at diagnosis
Study NCT05531123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg I.V. Q3W on the day 1
Study NCT05531123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8
Study NCT05531123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified hypofractionation
Description: * Whole bladder 44Gy / 16fractionation (If N1: Whole bladder + Pelvic nodes 44Gy / 16fractionation) (Positive lymph nodes can be dosed to the maximum tolerable dose)~* Tumor boost 11Gy / 4fractionation~* Radiosensitizing chemotherapy: DDP 75-80 mg/m2 weekly Q3W
Study NCT05234892 — intervention group
Intervention type: DEVICE
Intervention: ALTO endograft implantation
Description: Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
Study NCT06019130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine during induction chemotherapy in patients > 25 years with metastatic disease at diagnosis
Study NCT06019130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: After induction therapy in all patients
Study NCT06019130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: In patients \< 26 years after end of radiochemotherapy for 6 months
Study NCT06019130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
Study NCT06019130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
Study NCT06019130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
Study NCT05178147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression bandaging without reference to GraduCheck pressure measurements
Description: To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
Study NCT05178147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression bandaging using GraduCheck pressure measurements to monitor compression pressure
Description: To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
Study NCT06120881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
Study NCT06120881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
Study NCT05476679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012
Description: 50mg/ml drug formulation
Study NCT05476679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+Lidacaine injection prior treatment
Description: 5ml lidocaine will be injected 10 minutes before RZL-012 treatment
Study NCT05476679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+Medrol
Description: oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
Study NCT05476679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+Celecoxib+Zyrtec
Description: 200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
Study NCT05476679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+facial and neck wrap
Description: Universal Facial Band
Study NCT05514028 — intervention group
Intervention type: OTHER
Intervention: Salivary samples
Description: For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)
Study NCT05947344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-8591
Description: Seven dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg,80mg,120mg, 160mg, 200mg, 240mg.Expansion is planned in three dose groups of 120mg, 160mg, and 200mg.
Study NCT06535451 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
Study NCT04945174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory exercise combined with patient education and individual follow-up sessions
Description: 6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
Study NCT06478147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Nutritional Supplement
Description: Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast
Study NCT06478147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement + Whey Protein Hydrolysate
Description: Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast
Study NCT06478147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Hydrolysate + still water
Description: Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
Study NCT05505669 — intervention group
Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Study NCT06274190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bowel e-diary
Description: This bowel diary will be available on the smartphone in the form of an application.
Study NCT04058769 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Premedication Guide
Description: Software with guidelines recommendations for preoperative assessment
Study NCT05041439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Participants will receive 5 one-on-one sessions with a CHW over 6 months.
Study NCT05509634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20013 for injection；dexamethasone
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Study NCT05509634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
Description: fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Study NCT02763527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking reduction
Description: A brief intervention on smoking reduction plus a smoking reduction leaflet
Study NCT06189755 — intervention group
Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
Study NCT06410937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy without drain
Description: thyroidectomy without subcutaneous suction drain
Study NCT02763527 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation
Description: A brief advice on quitting plus a leaflet on smoking cessation
Study NCT05641493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HLX208+HLX10
Description: HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
Study NCT05253625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to a recorded lullaby.
Description: A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
Study NCT06477900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reception
Description: reception of 72 SMS encouraging physical activity and nutritional advice
Study NCT06261489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
Study NCT06261489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
Study NCT05337280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio OA/US
Description: Imagio optoacoustic/ultrasound
Study NCT06410937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy with drain
Description: hyroidectomy with subcutaneous suction drain
Study NCT05694429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product K cleanser and moisturizer
Description: Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
Study NCT05249010 — intervention group
Intervention type: PROCEDURE
Intervention: acupuncture and moxibustion
Description: Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
Study NCT06206499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: soft tissue augmentation
Description: Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants.
Study NCT06206499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue augmentation
Description: Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants.
Study NCT06507410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min.
Study NCT06507410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol combined with clonidine
Description: Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
Study NCT05024188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
Study NCT05024188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
Study NCT05024188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellules Pills
Description: 7 days of cellules placebo pills.
Study NCT06775431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Description: Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication
Study NCT06775431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally
Description: 0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
Study NCT06775366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam 6mg/kg/h was pumped intravenously for 2.5 min, Sufentanil 0.5 μg/kg and rocuronium 0.6mg/kg were injected intravenously, and endotracheal intubation was performed 3 minutes later. Remimazolam was then pumped at 1 mg/kg/h, the BIS was kept in the range of 40-60 through general anesthesia, and the remimazolam infusion rate was adjusted (0.5-3 mg/kg/h).If the BIS cannot be maintained at ≤ 60 or there are signs of potential inadequate anesthesia (such as cough, sweating, and patient movement), and the maximum infusion dose of remimazolam has been given, supplemental sedation with the remedial drug sevoflurane or propofol is used and the case is dismissed.
Study NCT06775366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol (2-3mg/kg), Sufentanil (0.5μg /kg), rocuronium (0.6mg/kg) were injected intravenously, and endotracheal intubation was performed for 3 minutes. Subsequently, propofol was pumped at 4-10mg/kg/h to maintain the BIS in the range of 40-60.
Study NCT06773663 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-Pentixafor PET/CT
Description: Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline.~The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling.~CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability.
Study NCT06776419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Ressonance Imaging
Description: CMR-protocol with gadolinium contrast
Study NCT06776419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rubidium-positron emission tomography and computer-tomography
Description: cardiac Rb-PET protocol
Study NCT06775236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYS6010 jnjection
Description: SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker
Study NCT06775236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: monotherapy chemotherapy
Description: Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)
Study NCT06775236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2051 tablets
Description: SYH2051 is a Selective ATM protein kinase inhibitor
Study NCT06776627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA)
Description: Adapted program: aerobic capacity, strength, endurance, flexibility, balance and proprioception tests. APA sessions take place over 12 weeks. There will be 2 to 3 sessions per week. Course of a session: - Warm-up: 10-15min: cycling or walking. - Moderate-intensity endurance activity: cycling, walking or swimming: 10min, the duration will be increased gradually up to a minimum of 30min at the end of the program. - Muscle strengthening: with polyarticular or monoarticular exercises targeting the upper limbs or lower limbs in alternation and sheathing. At the beginning: 8 exercises per session and 8 repetitions, 1 time per week. Objective will be to increase the number of repetitions and then integrate other exercises to reach 10 exercises with 12 repetitions, 2 times per week. - Stretching and balance: learning to stretch the muscle groups worked and then working on proprioception (bipodal, monopodal station, then double task). - Quiet time: relaxation through breathing 5 min.
Study NCT06776601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full process digital therapy intervention package
Description: Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
Study NCT06776289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Platelet rich fibrin will be used to fill an osteotomy after endodontic microsurgery is completed.
Study NCT06004310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Participants will be participated a 06 weeks comprehensive outpatient pulmonary rehabilitation which includes endurance training, strength training, patient education, relaxation techniques, psychological support and nutritional counselling.
Study NCT06161532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
Study NCT05478811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er,Cr:YSSG laser
Description: NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
Study NCT05478811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine final irrigation procedure will be done, NaOCl will not be activated by any method)